Driehaus Capital VKTX Position
Active11-Fund ConvergenceDriehaus Capital increased their position in Viking Therapeutics Inc. (VKTX) in Q4 2025, holding $21.0M worth of shares across 293,790 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
VKTX is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for VK2735 in 441 days (Jul 1, 2027), making the timing of Driehaus's position particularly relevant.
Short interest stands at 25.1% of float with 9.6 days to cover, indicating significant bearish positioning against Driehaus's long thesis.
About Viking Therapeutics Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Full company profile →Short Interest
25.1%
9.6 days to cover
Driehaus Capital VKTX Position History
Frequently Asked Questions
Does Driehaus Capital own VKTX?
Yes. As of Q4 2025, Driehaus Capital holds 293,790 shares of Viking Therapeutics Inc. (VKTX) valued at $21.0M. This data comes from their SEC 13F filing.
How many hedge funds own VKTX?
11 specialist biotech hedge funds currently hold VKTX, including Avoro Capital Advisors, Perceptive Advisors, Deerfield Management and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy VKTX?
Driehaus Capital's position in VKTX was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's VKTX position increasing or decreasing?
Driehaus Capital increased their VKTX position in the most recent quarter, adding 91,238 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VKTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →